UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

RTTNews | Pred 757 dňami
UroGen Pharma Says FDA Approves Plan For Rolling NDA Submission For UGN-102 From January 2024

(RTTNews) - Biotech company UroGen Pharma Ltd. (URGN) announced Tuesday that it has reached agreement with the U.S. Food and Drug Administration (FDA) on plans for submission of a New Drug Application (NDA) for UGN-102 (mitomycin) for intravesical solution.

The FDA indicated that the current clinical development plan for UGN-102, which includes evaluation of duration of complete response (CR) at 12 months from the pivotal ENVISION trial, will support submission of an NDA for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

The FDA also agreed that the UGN-102 NDA can utilize a rolling review, allowing for early submission of the Chemistry, Manufacturing and Controls (CMC) sections of the NDA, which is planned for January 2024.

If approved, UGN-102 has the potential to introduce a new non-surgical treatment paradigm for LG-IR-NMIBC, a subset of bladder cancer patients characterized by high recurrence rates and the need for multiple surgeries.

The UGN-102 clinical development plan centers around the Phase 3 ENVISION pivotal trial and is supported by robust clinical data from the ATLAS Phase 3 and OPTIMA Phase 2b trials.

read more
UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

UroGen Pharma Files Patent Infringement Lawsuit Against Teva Pharma

Biotech company UroGen Pharma Ltd. (URGN) announced Wednesday that it has filed a lawsuit in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., and Teva Pharmaceutical Industries, Ltd. (TEVA), alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069.
RTTNews | Pred 574 dňami
Yen Falls After BoJ Rate Decision

Yen Falls After BoJ Rate Decision

The Japanese yen weakened against other major currencies in the Asian session on Thursday, after the Bank of Japan left its interest rate unchanged, and kept its real growth and inflation outlook more or less unchanged.
RTTNews | Pred 32 minútami
French GDP Growth Accelerates Unexpectedly

French GDP Growth Accelerates Unexpectedly

France's economic growth accelerated in the third quarter despite political uncertainty and trade tensions, official data revealed on Thursday. Gross domestic product registered a quarterly growth of 0.5 percent, following a 0.3 percent rise in the second quarter, the statistical office INSEE reported. The growth was expected to ease to 0.2 percent.
RTTNews | Pred 48 minútami
Bank Of Japan Keeps Key Rate On Hold

Bank Of Japan Keeps Key Rate On Hold

The Bank of Japan left its interest rate unchanged even as inflation continued to remain above 2 percent, and also left its real growth and inflation outlook more or less unchanged. The policy board of the Bank of Japan decided, by a 7-2 majority vote, to hold the uncollateralized overnight call rate at around 0.5 percent.
RTTNews | Pred 1 h 53 min
Sensex, Nifty Drift Lower In Cautious Trade

Sensex, Nifty Drift Lower In Cautious Trade

Indian shares traded lower on Thursday as investors reacted to hawkish remarks from Fed Chair Jerome Powell and a mixed bag of U.S. tech earnings.
RTTNews | Pred 3 h 36 min
Yen Falls Against Majors

Yen Falls Against Majors

The Japanese yen weakened against other major currencies in the Asian session on Thursday.
RTTNews | Pred 4 h 3 min
Australian Market Trims Early Losses In Mid-market

Australian Market Trims Early Losses In Mid-market

The Australian market is trimming its early losses in mid-market moves on Thursday, but adding to the losses in the previous two sessions, following the mixed cues from Wall Street overnight. The benchmark S&P/ASX 200 is falling to near the 8,900 level, with gains in iron ore miners and financial stocks partially offset by weakness in technology stocks.
RTTNews | Pred 4 h 50 min